ArticleBlood2012
Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.
Article in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 52 citations in OpenAlex.
- Type I interferon upregulates Bak and contributes to T cell loss during human immunodeficiency virus (HIV) infection.PLoS pathogens · 2013Trial
- Intact type I Interferon production and IRF7 function in sooty mangabeys.PLoS pathogens · 2013Trial
- Review
- Microglia and macrophages alterations in the CNS during acute SIV infection: A single-cell analysis in rhesus macaques.PLoS pathogens · 2024Article
- Microglia and macrophages alterations in the CNS during acute SIV infection: a single-cell analysis in rhesus macaques.bioRxiv : the preprint server for biology · 2024Article
- IFNα Subtypes in HIV Infection and Immunity.Viruses · 2024Review
- Toll-like receptor 7 protects against intestinal inflammation and restricts the development of colonic tissue-resident memory CD8Frontiers in immunology · 2024Article
- Upregulation of IFN-stimulated genes persists beyond the transitory broad immunologic changes of acute HIV-1 infection.iScience · 2023Article
- IL-21 and IFNα therapy rescues terminally differentiated NK cells and limits SIV reservoir in ART-treated macaques.Nature communications · 2021Article
- HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.AIDS research and human retroviruses · 2019Review
- Diverse Immunomodulatory Effects of Individual IFNα Subtypes on Virus-Specific CD8Frontiers in immunology · 2019Article
- Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration.PLoS pathogens · 2018Article
- Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.Journal of virology · 2018Article
- Accumulation of follicular CD8+ T cells in pathogenic SIV infection.The Journal of clinical investigation · 2018Article
- Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection.Immunity · 2018Article
- Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.Cytokine & growth factor reviews · 2018Review
- The TRAIL: TRAILshort Axis in HIV Immunopathology.Critical reviews in immunology · 2018Review
- Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers.Frontiers in pharmacology · 2018Article
- Lymph Node Cellular and Viral Dynamics in Natural Hosts and Impact for HIV Cure Strategies.Frontiers in immunology · 2018Review
- Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
A key feature differentiating nonpathogenic SIV infection of sooty mangabeys (SMs) from pathogenic HIV/SIV infections is the rapid resolution of type I IFN (IFN-I) responses and IFN-stimulated gene expression during the acute-to-chronic phase transition and the establishment of an immune quiescent state that persists throughout the chronic infection. We hypothesized that low levels of IFN-I signaling may help to prevent chronic immune activation and disease progression in SIV-infected SMs. To assess the effects of IFN-I signaling in this setting, in the present study, we administered recombinant rhesus macaque IFNα2-IgFc (rmIFNα2) to 8 naturally SIV-infected SMs weekly for 16 weeks. Gene-expression profiling revealed a strong up-regulation of IFN-stimulated genes in the blood of treated animals, confirming the reagent's bioactivity. Interestingly, we observed an approximately 1-log decrease in viral load that persisted through day 35 of treatment. Flow cytometric analysis of lymphocytes in the blood, lymph nodes, and rectal biopsies did not reveal a significant decline of CD4(+) T cells, a robust increase in lymphocyte activation, or change in the level of SIV-specific CD8(+) T cells. The results of the present study indicate that administration of type I IFNs in SIV-infected SMs induces a significant anti-viral effect that is not associated with a detectable increase in chronic immune activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.